May 16, 2013
11:00 am to 12:00 pm EDT

Sponsored by

Symposium Course Description:

Understanding the roles of endogenous voltage gradients, ion flows, and electric fields will contribute to the basic understanding of numerous cellular processes. The EFS (Electric Field Stimulation) capability of the Cellaxess® Elektra discovery platform enables a wide range of new opportunities in cell biology research as the system allows for high throughput in-situ EFS experiments on cell cultures and tissues in 96 or 384-well plates. By combining the platform’s ability to electrically stimulate cells with highly sensitive dynamic imaging and reporters, we create biologically relevant, high quality phenotypic assays for compound characterization and target validation for our partners. In this webinar, we will describe the underlying core technology and demonstrate its applicability using recent data from our cardiovascular and CNS/pain assay development projects.

The Attendees of This Webinar Will:

• Understand how the Platform can be applied to enable novel, excitable cellular assays
• Gain knowledge of compound profiling to advance research in the CNS and pain therapeutic fields
• Get a comprehensive understanding of the principles of operation of the Cellaxess Elektra Platform and Services
• Learn workflows and principles for key assay development and protocol steps

Who Should Attend:

• Program Managers
• Alliance Managers
• Clinical Development Leads
• Research & Development scientists in the following fields: CNS, Neurobiology, Neuroscience, Dementia, Translational science, Lead Discovery, External Drug Discovery, in vitro Screening, Compound Profiling, High Content Biology, Electrophysiology, Ion Channels
• Assay Developers
• Lab Managers
• External Research Solutions Managers
• Scientific Collaboration and Business Development Managers

Program Agenda:

11:00 – 11:15 am - Cellaxess Elektra Discovery platform, core technology overview
11:15 – 11:30 am - Cellectricon Discovery services overview
11:30 am – 12:00 pm - Development of phenotypic assays for CNS/Pain research and Cardiovascular research

Speaker Information:

Mattias Karlsson, Ph.D.

Chief Technology Officer, Cellectricon

Mattias was involved in founding Cellectricon, and joined the company on a full-time basis in 2003 as VP R&D to develop the product portfolio. He has contributed to the company with most of the patents and the conceptual work to define products from existing IP. Mr. Karlsson currently holds the position of VP technology and science, and is responsible for continued development of the technology portfolio. He is also responsible for business development activities. Mattias has a Ph.D. in chemistry from Chalmers University of Technology in Gothenburg and a M.Sc. in analytical chemistry from Gothenburg University.

Paul Karila, Ph.D.

VP of Discovery Services, Cellectricon

Paul is responsible for building and providing Discovery Services at Cellectricon’s labs in Mölndal, Sweden. Paul joined Cellectricon from AstraZeneca (AZ) where he held leadership positions at the Departments of Molecular Pharmacology and Neuroscience. Paul led teams responsible for ion channel and GPCR profiling in LI-LO phase, mainly on analgesia targets, and most recently a target identification/target validation team focusing on implementing native, human tissue use in the drug discovery process. Prior to joining AZ, Paul was a Postdoctoral Fellow at School of Medicine, University of Pittsburgh, PA, USA (1997 to 1998) studying neurobiology using electrophysiological methods. Paul earned his PhD at the University of Gothenburg, Sweden in 1997